Cytokine-Based Drug Development Summit on June 27-29, 2023 in Boston, United States

New doors open for Cytokine drug developers to treat diseases both in and beyond oncology with novel masking and tissue targeting mechanisms and the abundance of preclinical and clinical efficacy data as more companies get additional funding to boost their pipelines.

Now's the time to join forces with key decision-makers including Sanofi, Moderna, Xencor, CytomX and more at the 4th Cytokine-Based Drug Development Summit, the only industry focused event exclusively addressing your discovery, translational and reverse translational challenges.

This meeting will equip you with the latest scientific insights to develop a cytokine drug with reduced toxicities, enabling you to dose at the right level and witness greater clinical benefit to patients.

With a focus on IL-2, IL-12, IL-7 and more across oncology, autoimmune and infectious diseases, learn new approaches to limiting toxicities, how to develop an accurate and reliable preclinical model, as well as lessons from clinical development to inform future design principles.

URLs:

Tickets: https://go.evvnt.com/1561164-2?pid=10008

Brochure: https://go.evvnt.com/1561164-3?pid=10008

Prices:
Conference Only - Drug Developer: USD 2899.00,
Conference + Pre - Conference Workshop Day - Drug Developer: USD 4097.00,
Conference Only - Service Provider: USD 3599.00,
Conference + Pre - Conference Workshop Day - Service Provider: USD 4997.00

Speakers: Alexandra Wolfarth, Senior Scientist, NeoImmuneTech Inc., Angus Sinclair, SVP Immuno-oncology Research, IGM Biosciences, Asaf Maoz, Clinical Fellow, Brigham and Women's - Dana Farber Cancer Institute, Byung Ha Lee, SVP and CSO, NeoImmuneTech Inc., Donald Shaffer, Head of Precision Cytokines and Cell Therapies, Sanofi, Erwan Le Scolan, Associate Director, CytomX Therapeutics, Eva Vanamee, Co-Founder, FusionBio, Inc., Genevieve Inchauspe, ImmunResQ Department Head, Transgene, Giovanni Abbadessa, Vice President and Head of Early Development and Oncology, Sanofi Genzyme, Giulio Paciotti, Chief Science Officer, CytImmune Sciences, Hilario Ramos, Head Of Immunology, Invenra Inc., Irena Adkins, Director Pharmacology, SOTIO, Jamie Spangler, Assistant Professor - Biomedical, Chemical and Biomolecular Engineering, Johns Hopkins, John Cini, Chief Scientific Officer and Co-Founder, Sonnet BioTherapeutics Inc., Joshua Heiber, Principal Scientist, Alkermes, Matthew Bernett, Senior Director, Protein Engineering, Xencor, Michael Abadier, Director - Translational Medicine Oncology, Moderna, Nicki Panoskaltsis, Professor in Personalised Therapeutics, Trinity College Dublin, Nicolas Poirier, CEO-CSO, OSE Immunotherapeutics, Nikolai Kley, Founder, President and Chief Executive Officer, Orionis Biosciences LLC, Omid Veiseh, Co-founder, Avenge Bio, Richard Kenney, Chief Medical Officer, Sonnet BioTherapeutics Inc., Sam Murphy, Chief Executive Officer, Salubris Biotherapeutics Inc., Sara Ferrando-Martinez, Principal Scientist, NeoImmuneTech Inc., Susan Richards, Vice President - Translational Medicine and Early Development, Sanofi

Time: 09:00 to 16:00